Cargando…

BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy

BRAF and MEK inhibitors (BRAFi/MEKi), the standard treatment for patients with BRAF(V600) mutated melanoma, are currently explored in combination with various immunotherapies, notably checkpoint inhibitors and adoptive transfer of receptor-transfected T cells. Since two BRAFi/MEKi combinations with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dörrie, Jan, Babalija, Lek, Hoyer, Stefanie, Gerer, Kerstin F., Schuler, Gerold, Heinzerling, Lucie, Schaft, Niels
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796234/ https://www.ncbi.nlm.nih.gov/pubmed/29346301 http://dx.doi.org/10.3390/ijms19010289

Ejemplares similares

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
por: Hoyer, Stefanie, et al.
Publicado: (2021)

RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
por: Harrer, Dennis C., et al.
Publicado: (2017)

Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination
por: Gerer, Kerstin F., et al.
Publicado: (2017)

Electroporated Antigen-Encoding mRNA Is Not a Danger Signal to Human Mature Monocyte-Derived Dendritic Cells
por: Hoyer, Stefanie, et al.
Publicado: (2015)

Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update
por: Dörrie, Jan, et al.
Publicado: (2020)

CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia
por: Harrer, Dennis C., et al.
Publicado: (2019)

Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance
por: Wiesinger, Manuel, et al.
Publicado: (2019)

NF-κB activation triggers NK-cell stimulation by monocyte-derived dendritic cells
por: Bosch, Naomi C., et al.
Publicado: (2019)

A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma
por: Koch, Elias A. T., et al.
Publicado: (2022)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
por: Heinzerling, Lucie, et al.
Publicado: (2019)

Just One Position-Independent Lysine Residue Can Direct MelanA into Proteasomal Degradation following N-Terminal Fusion of Ubiquitin
por: Setz, Christian, et al.
Publicado: (2013)

A Chimeric IL-15/IL-15Rα Molecule Expressed on NFκB-Activated Dendritic Cells Supports Their Capability to Activate Natural Killer Cells †
por: Bosch, Naomi C., et al.
Publicado: (2021)

Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma
por: Lau, Peter Kar Han, et al.
Publicado: (2021)

BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
por: Peiffer, Lukas, et al.
Publicado: (2020)

CARs: Beyond T Cells and T Cell-Derived Signaling Domains
por: Sievers, Nico M., et al.
Publicado: (2020)

Network- and systems-based re-engineering of dendritic cells with non-coding RNAs for cancer immunotherapy
por: Lai, Xin, et al.
Publicado: (2021)

Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study
por: Salzmann, Martin, et al.
Publicado: (2023)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

The future of affordable cancer immunotherapy
por: Schaft, Niels, et al.
Publicado: (2023)

T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options
por: Gehrcken, Laura, et al.
Publicado: (2021)

CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges
por: Harrer, Dennis C., et al.
Publicado: (2019)

Kutane Lymphome
por: Heinzerling, Lucie, et al.
Publicado: (2013)

Human Adenovirus-Specific γ/δ and CD8(+) T Cells Generated by T-Cell Receptor Transfection to Treat Adenovirus Infection after Allogeneic Stem Cell Transplantation
por: Dörrie, Jan, et al.
Publicado: (2014)

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2
por: Chen, Wenjing, et al.
Publicado: (2023)

Successful BRAF/MEK inhibition in a patient with BRAF(V600E)-mutated extrapancreatic acinar cell carcinoma
por: Busch, Elena, et al.
Publicado: (2020)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

Reply: Intra-patient heterogeneity of BRAF mutation status: fact or fiction?
por: Heinzerling, L, et al.
Publicado: (2014)

Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma
por: Krückel, Annika, et al.
Publicado: (2019)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
por: Stones, Clare J., et al.
Publicado: (2013)

Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy
por: Estep, Anne L., et al.
Publicado: (2007)

Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients
por: Kirchberger, Michael Constantin, et al.
Publicado: (2018)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
por: Turner, Elizabeth, et al.
Publicado: (2022)

Fibroblasts Influence Metastatic Melanoma Cell Sensitivity to Combined BRAF and MEK Inhibition
por: Morales, Delphine, et al.
Publicado: (2021)

Multi-Level Computational Modeling of Anti-Cancer Dendritic Cell Vaccination Utilized to Select Molecular Targets for Therapy Optimization
por: Lai, Xin, et al.
Publicado: (2022)

BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition
por: Campos, Maira P., et al.
Publicado: (2018)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports
por: Schliep, Stefan, et al.
Publicado: (2018)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h4id2d8riad0q486u7bt753719